Neuroendocrine Carcinoma Treatment Market- Rising healthcare expenditure, coupled with expanding patient pool of cancer, will boost the global market

Prominently driven by collaborative strategies for speedy research of drugs for Neuroendocrine Carcinoma Treatment, the market is set for an impressive growth during the forecast period. Rising number of patients diagnosed with neuroendocrine carcinoma, increasing number of patients seeking treatment, and innovative drugs under clinical trials, along with research grants from government agencies are expected to boost the growth of the neuroendocrine carcinoma treatment market during the forecast period. In June 2019, Progenics Pharmaceuticals presented long-term follow up data from its pivotal phase 2 study of Azdera, which showed overall survival of 73.1% at two years and 44.2% at four years, improving the overall survival rate in patients suffering from neuroendocrine carcinoma.

The global neuroendocrine carcinoma treatment market was valued US$ 1.3 Bn in 2018, and is expected to exhibit a CAGR of 7% during the forecast period
(2019 - 2029).

“Rising number of patients seeking treatment along with collaborative actions by manufacturers to provide novel treatment options, and increasing research grants for drug innovation are anticipated to boost neuroendocrine carcinoma treatment market growth during the forecast period.”

To remain ‘ahead’ of your competitors, request for a sample- https://www.futuremarketinsights.com/reports/sample/rep-gb-1278

Key Takeaways of Neuroendocrine Carcinoma Treatment Market Study

Owing to large patient pool seeking treatment for gastric neuroendocrine tumors, the segment is expected to dominate the neuroendocrine carcinoma treatment market.
Somatostatin analog therapy for vasoactive intestinal peptide, carcinoid tumors, pituitary adenomas, and other indications is expected to gain traction over targeted therapy and chemotherapy during the forecast period.
Hospitals remain prominent end users as compared to clinics, as hospitalization of patients is required to monitor the progress of therapy deployed during the treatment of neuroendocrine carcinoma.
North America is expected dominate the global neuroendocrine carcinoma treatment market, owing to improved healthcare infrastructure, favorable reimbursement scenario, increasing research grants, and large target patient pool.
Get Going with TOC Of Market Report- https://www.futuremarketinsights.com/reports/neuroendocrine-carcinoma-market/table-of-content

Neuroendocrine Carcinoma Drug Manufacturers Focusing on Collaborations to Gain Competitive Advantage

AbbVie Inc., Advanced Accelerator Applications, and F. Hoffmann-La Roche are among the leading manufacturers that operate in the neuroendocrine carcinoma treatment market. In December 2019, AbbVie and Scripps Research announced a collaboration to develop a broad range of new therapeutics in the areas of oncology, immunology, neurology, and fibrosis. This strategic move is expected to cater to the needs of patients by innovating refined novel medicines. Eisai’s Levinima was approved in combination with Novartis’s Afinitor for the treatment of advanced renal cell carcinoma, in May 2016. This collaboration agreement has set the terms, whereby the sales teams from both pharmaceutical companies will promote the availability of this combination regimen to health service providers. In November 2017, VBL Therapeutics and NanoCarrier Co., Ltd. signed an exclusive agreement for VB-111 for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan. In December 2018, Advanced Accelerator Applications entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical Co. to develop and commercialize radiolabeled molecules for oncology indications.

More Valuable Insights on Neuroendocrine Carcinoma Treatment Market

Neuroendocrine carcinoma treatment market, a new study from Future Market Insights, provides unparalleled insights on the evolution of the market during 2014–2018, and presents demand projections for 2019–2029, on the basis of disease indication (gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and appendiceal neuroendocrine tumors), treatment type (somatostatin analogs, targeted therapy, and chemotherapy), end user (hospitals, clinics, oncology centers, and ambulatory surgical centers), across seven major regions.

For in-depth competitive analysis, Buy Now- https://www.futuremarketinsights.com/checkout/1278

Contact

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

This release was published on openPR.